Clinical trial · no report yet · Phase 2/Phase 3
NEO-BLAST
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
- NCT06537154 ↗
- Recruiting
- Peter Black
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Active Surveillance Versus Definitive Local Therapy for Patients Showing Clinical Complete Response Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Muscle-Invasive Bladder Carcinoma
- Interventions
- Active Surveillance; Control arm - Definitive bladder treatment
- Arms
- cCR, Standard of care · Active comparator
- cCR, Active surveillance · Experimental
- non-cCR, standard of care · No intervention
- Enrollment
- 688 (estimated)
- Primary outcomes
- Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2)
- Metastasis free survival at 2 years (phase 3)
- Sponsor
- Peter Black with University of British Columbia, Canadian Institutes of Health Research (CIHR)
- Start
- Jul 28, 2025
- Primary completion
- Dec 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06537154 · updated Jul 30, 2025
Publications
linked from the registry- St-Laurent MP, Eigl BJ, Tyldesley S, Yuan R, Chang S, Vandekerkhove G, Black PC. NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol. Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00198-7. doi: 10.1016/j.euo.2026.07.008. Online ahead of print. PubMed 42567733